Amyloidosis is not a specific disease but a group of diseases characterized by an accumulation of protein deposits. Normally, blood cells produce antibodies to either protect against infection or fight disease. Once they have achieved their mission, these proteins, or amyloids, are broken down and recycled. In some cases, though, an overproduction of proteins occurs and they start to build up outside the cells. These buildups can cause problems in various organs or systems anywhere in the body.

» Current Clinical Trial Listings:

---

Displaying: 1 to 8 (12) - Previous page | Next page

---

1)	Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) Amyloidosis
2)	Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis Amyloidosis
3)	Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis Amyloidosis
4)	Study of Systemic Amyloidosis Presentation and Prognosis Amyloidosis
5)	The Effect of Diflunisal on Familial Amyloidosis Familial Amyloid Polyneuropathy; Familial Amyloidosis
6)	A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis Primary Amyloidosis
7)	Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis Transthyretin Amyloidosis
8)	Radioimmunoimaging of AL Amyloidosis Primary Amyloidosis

---

Displaying: 1 to 8 (12) - Previous page | Next page